Skip to content
Biodatica
Start free

Allist Pharmaceuticals, Inc.

Beijing, Beijing Municipality

OncologybispecificPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

6w agoTrial registeredJun 3, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Momentum 76 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

471 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jul 31, 2025

    NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112, Bispecific Antibody · NOT_YET_RECRUITING · sponsor: Yang Fan, MD · A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

    ClinicalTrials.gov · NCT07086326 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jul 1, 2025

    Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy · RECRUITING · sponsor: Peking University People's Hospital · Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT07359040 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    May 28, 2025

    NSCLC, Adjuvant Treatment · RECRUITING · sponsor: Allist Pharmaceuticals, Inc. · A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

    ClinicalTrials.gov · NCT07010419 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources